These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 32355541)
41. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents. Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366 [TBL] [Abstract][Full Text] [Related]
42. Rosiglitazone ameliorates senescence and promotes apoptosis in ovarian cancer induced by olaparib. Wang Z; Gao J; Ohno Y; Liu H; Xu C Cancer Chemother Pharmacol; 2020 Feb; 85(2):273-284. PubMed ID: 31907647 [TBL] [Abstract][Full Text] [Related]
43. Aurora-A/SOX8/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells. Sun H; Wang H; Wang X; Aoki Y; Wang X; Yang Y; Cheng X; Wang Z; Wang X Theranostics; 2020; 10(15):6928-6945. PubMed ID: 32550913 [No Abstract] [Full Text] [Related]
45. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway. Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507 [TBL] [Abstract][Full Text] [Related]
46. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003 [TBL] [Abstract][Full Text] [Related]
47. Association of ALDH1A1-NEK-2 axis in cisplatin resistance in ovarian cancer cells. Uddin MH; Kim B; Cho U; Azmi AS; Song YS Heliyon; 2020 Nov; 6(11):e05442. PubMed ID: 33241139 [TBL] [Abstract][Full Text] [Related]
48. TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer. Han X; Zhou Y; You Y; Lu J; Wang L; Hou H; Li J; Chen W; Zhao L; Li X Cell Biol Int; 2017 Apr; 41(4):405-414. PubMed ID: 28150354 [TBL] [Abstract][Full Text] [Related]
49. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells. Gong TT; Liu XD; Zhan ZP; Wu QJ Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713 [TBL] [Abstract][Full Text] [Related]
50. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer. Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822 [TBL] [Abstract][Full Text] [Related]
51. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species. Yang YI; Kim JH; Lee KT; Choi JH Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308 [TBL] [Abstract][Full Text] [Related]
52. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Mangala LS; Zuzel V; Schmandt R; Leshane ES; Halder JB; Armaiz-Pena GN; Spannuth WA; Tanaka T; Shahzad MM; Lin YG; Nick AM; Danes CG; Lee JW; Jennings NB; Vivas-Mejia PE; Wolf JK; Coleman RL; Siddik ZH; Lopez-Berestein G; Lutsenko S; Sood AK Clin Cancer Res; 2009 Jun; 15(11):3770-80. PubMed ID: 19470734 [TBL] [Abstract][Full Text] [Related]
53. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Henkels KM; Turchi JJ Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248 [TBL] [Abstract][Full Text] [Related]
54. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines. Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764 [TBL] [Abstract][Full Text] [Related]
55. MiR-106a targets Mcl-1 to suppress cisplatin resistance of ovarian cancer A2780 cells. Rao YM; Shi HR; Ji M; Chen CH J Huazhong Univ Sci Technolog Med Sci; 2013 Aug; 33(4):567-572. PubMed ID: 23904379 [TBL] [Abstract][Full Text] [Related]
56. Impaired cisplatin influx in an A2780 mutant cell line: evidence for a putative, cis-configuration-specific, platinum influx transporter. Helleman J; Burger H; Hamelers IH; Boersma AW; de Kroon AI; Stoter G; Nooter K Cancer Biol Ther; 2006 Aug; 5(8):943-9. PubMed ID: 16775422 [TBL] [Abstract][Full Text] [Related]
57. Nivolumab effectively inhibit platinum-resistant ovarian cancer cells via induction of cell apoptosis and inhibition of ADAM17 expression. Sun LM; Liu YC; Li W; Liu S; Liu HX; Li LW; Ma R Eur Rev Med Pharmacol Sci; 2017 Mar; 21(6):1198-1205. PubMed ID: 28387913 [TBL] [Abstract][Full Text] [Related]
58. Tribbles 2 mediates cisplatin sensitivity and DNA damage response in epithelial ovarian cancer. Kritsch D; Hoffmann F; Steinbach D; Jansen L; Mary Photini S; Gajda M; Mosig AS; Sonnemann J; Peters S; Melnikova M; Thomale J; Dürst M; Runnebaum IB; Häfner N Int J Cancer; 2017 Oct; 141(8):1600-1614. PubMed ID: 28670762 [TBL] [Abstract][Full Text] [Related]
59. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB pathway. Zou W; Ma X; Hua W; Chen B; Cai G Oncol Rep; 2015 Dec; 34(6):3256-63. PubMed ID: 26503358 [TBL] [Abstract][Full Text] [Related]
60. miR-509-3p enhances platinum drug sensitivity in ovarian cancer. Niu L; Ni H; Hou Y; Du Q; Li H Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]